ClearPoint Neuro, Inc. Appoints Ellisa Cholapranee as General Counsel

Companies in the Global Vaccine Delivery Devices Market Expedite Product Innovations to Stay at Forefront in the Market in the COVID-19 Pandemic

Fact.MR has recently compiled a report, which reveals that the vaccine delivery devices market globally is projected to reflect an impressive CAGR over the forecast period, 2017 – 2022.

Sirtex Medical and BlackSwan Vascular Report 1st Patient Enrolled in Pivotal LAVA Study

The LAVA Study, which stands for Liquid Embolization of Arterial Hemorrhages in Peripheral Vasculature, is a prospective, multicenter single-arm study of 113 subjects at 20 investigational sites in the U.S.

March 24, 2021

ClearPoint Neuro, Inc. is a global therapy-enabling platform company providing navigation and delivery to the brain. Today announced that Ellisa Cholapranee will join the Company as General Counsel on April 5, 2021.

Ellisa Cholapranee will report directly to Joe Burnett, ClearPoint Neuro’s Chief Executive Officer, and serve as a member of the Company’s senior leadership team.

“Ellisa is a tremendous addition to our capable and growing leadership team,” commented Joe Burnett, President, and CEO of ClearPoint Neuro. “Not only does Ellisa offer the broad experience in compliance, contracting, and strategy, but like our Company itself, she has experience in both medical devices and biologics and drug delivery. Her insight having worked extensively as a partner to the pharma industry will enhance communication and efficiency, both in signing new gene therapy and stem cell partners, as well as broaching more sophisticated risk-sharing agreements with our collaborators.”

Ellisa Cholapranee brings to the Company almost a decade of experience advising companies in the life science and medical device sectors on legal, business, and compliance issues. Before joining the Company, she was Senior Legal Counsel for the cardiovascular devices division at Philips.

Prior to that, Ms. Cholapranee served as Senior Corporate Counsel at MilliporeSigma, a global life science company focused on providing solutions to pharmaceutical companies in every step of the biotech production chain, from research to drug manufacturing. She also has several years’ experience in the corporate and financial services departments of leading law firms in Boston and Chicago, where she counseled clients in the areas of corporate law, public offerings, mergers and acquisitions, and venture capital. Ms. Cholapranee holds a Bachelor of Science in Mathematics from Carnegie Mellon University and a J.D. from the Northwestern University Pritzker School of Law.

“I am thrilled to join ClearPoint at such an exciting phase of the Company’s growth,” stated Ellisa Cholapranee. “ClearPoint’s technology and team are truly impressive. I look forward to helping build upon the many successes of the Company.”

spot_img

DON'T MISS

Related Articles